How to Value a Non-Emergency Medical Transportation Company in 2026

Non-emergency medical transportation — NEMT — is one of the most interesting sectors in the lower middle market right now. It's recession-resistant, reimbursed by Medicaid (so revenue is effectively backstopped by state governments), growing with the aging population, and fragmented enough that consolidators are still actively rolling up operators. It's also one of the most operationally complex businesses you can buy.

I've worked on NEMT transactions ranging from 15-van single-county operators up to multi-state platforms with 400+ vehicles. The valuation dynamics compress into a remarkably consistent framework, but there are landmines specific to this industry that destroy value if you don't understand them.

The Baseline: 4-7x EBITDA

NEMT operators trade at 4.0-7.0x adjusted EBITDA in the current market, with meaningful dispersion based on size, contract mix, and payer exposure.

The low end (4-5x) applies to operators under $500K EBITDA who rely heavily on trip-by-trip broker assignments and have limited direct payer contracts. The high end (6-7x) applies to operators above $2M EBITDA with direct managed care organization (MCO) contracts, wheelchair and stretcher capability, and meaningful scale in a specific state.

Platform-scale operators — ModivCare (formerly LogistiCare + Provado), MTM, Verida, American Logistics — trade at 8-10x EBITDA at the parent level, but that's platform valuation. When they acquire tuck-ins, they pay 5-6x EBITDA for smaller operators.

Compare that to airport shuttle or limo operators at 2-4x SDE, and you can see why transportation entrepreneurs have been shifting capacity from traditional ground transport into NEMT over the last five years.

Understanding the NEMT Payment Stack

To value an NEMT operator correctly, you have to understand how the money flows. It's not obvious to people coming from other transportation sectors.

Medicaid covers NEMT as a mandatory benefit for eligible beneficiaries. States pay for it, but most states contract the administration out to a transportation broker — the biggest names are ModivCare, MTM, Verida (formerly Southeastrans), and American Logistics. The broker then contracts with individual transportation providers (that's your NEMT operator) to actually run the trips.

The broker typically takes 20-35% of the state reimbursement. The provider gets what's left, usually on a per-trip rate structure: a base pickup fee ($12-$25), a per-loaded-mile rate ($1.80-$3.50), and wait-time or no-show fees. Wheelchair and stretcher trips pay significantly more — often 2-4x the ambulatory rate.

This matters for valuation because who pays you affects how a buyer values the revenue:

• Broker-sourced trips (ModivCare, MTM, Verida): Worth 4-5x EBITDA. Stable volume but the broker can reassign trips to competitors anytime, and rate negotiations favor the broker.
• Direct MCO contracts (Molina, Centene/WellCare, Humana, UnitedHealthcare): Worth 5-6.5x EBITDA. Higher rates, longer-term agreements, more defensible.
• Direct state Medicaid fee-for-service: Worth 5-6x EBITDA. Rate-stable but subject to state budget pressures.
• Private-pay and facility contracts (dialysis centers, assisted living, rehab facilities): Worth 6-7x EBITDA. Often the highest margins and most defensible.

A $10M revenue operator that's 90% ModivCare trips is a very different asset than a $10M revenue operator that's 40% direct MCO contracts plus 30% facility contracts plus 30% broker. Buyers will segregate the book and value each bucket separately.

Broker Concentration Is the #1 Risk

If 60%+ of your revenue comes from a single broker, you have a concentration problem that will absolutely impact your multiple. Here's why.

Transportation brokers regularly renegotiate rates with their provider network. They can (and do) cut per-trip rates 5-15% in a single year when state reimbursements change. They can shift trip volume to competing providers in your service area overnight. And if they lose the state contract to a different broker, your entire revenue stream flips overnight.

I've seen a Georgia NEMT operator lose 70% of their volume in 90 days when the state shifted from Verida to LogistiCare in 2016. The owner had built a $6M revenue, $900K EBITDA business that collapsed to $2M revenue and break-even literally overnight. The business was unsellable at any multiple until they rebuilt their mix.

Buyers know this history. They will ask for:

• Revenue concentration by broker (and by MCO)
• Historical trip volume trends by broker
• Current per-trip rates vs 3 years ago
• Any rate cut notices or contract modifications
• Broker contract expiration schedules

Operators with diversified books and meaningful direct MCO contracts get premium multiples. Operators with 80% concentration in one broker get discounted, often heavily.

Fleet Mix and Capability

Not all NEMT vehicles are created equal. Buyers value capability, not just count.

• Ambulatory sedans and minivans: The commodity layer. Toyota Siennas, Dodge Caravans, Ford Transits. Easy to staff, easy to replace, low margin per trip.
• Wheelchair-accessible vehicles (WAVs): The middle tier. Ford Transits and Dodge ProMasters with rear-entry ramps and wheelchair securements. Higher trip rates ($45-$90 per trip vs $20-$40 ambulatory).
• Stretcher-capable vehicles: The highest-margin layer. Specially equipped vans that can transport bedridden patients who don't need an ambulance. Trip rates can exceed $150 each way. Fewer competitors, more defensible.
• Bariatric transport: A niche but lucrative capability. Specialized vehicles and lifts for patients over 400 lbs. Very few competitors in most markets.

An operator with 40% wheelchair and stretcher capability will trade at a meaningful premium to an operator with 100% ambulatory, even at the same revenue level, because the higher-acuity trips are more defensible and more profitable. I've seen wheelchair-heavy operators trade at 6.5x EBITDA in markets where pure ambulatory operators were getting 4x.

Who's Actually Buying NEMT

The buyer universe is active and well-capitalized:

• ModivCare: Publicly traded (NASDAQ: MODV). Has made dozens of tuck-in acquisitions over the last decade. Typical target: $5M+ EBITDA regional operators.
• MTM Inc.: Privately held. Active acquirer in markets where they're expanding their managed care footprint.
• Verida: Southeastern focus, PE-backed (Nautic Partners). Selective acquirer.
• American Logistics Company: Platform focused on direct MCO contracts. Acquires operators who fit their market strategy.
• Regional PE platforms: Several private equity firms have built regional NEMT platforms — Roundtable Healthcare Partners, Edgewater Capital Partners, and others have been active. These are typically the highest-multiple buyers.
• Local competitors: For sub-$1M EBITDA deals, another local operator looking to expand routes is the most common buyer at 4-5x.

What Actually Kills NEMT Value

Compliance and billing issues. NEMT is a Medicaid-reimbursed business, which means fraud, waste, and abuse scrutiny. A history of claim denials, audit findings, or (worst case) a Medicaid Fraud Control Unit investigation is a deal-killer. Buyers will pull your denial rates and audit history.

Driver workforce instability. NEMT drivers turn over at industry rates of 40-60% annually. Operators who've gotten retention under 25% have a real moat. Operators with revolving-door staffing get discounted because buyers model the cost of recruiting and training replacement drivers.

Broker contract renegotiations pending. If ModivCare or MTM is about to cut your per-trip rates (and operators usually know this is coming months ahead), the buyer will demand either a price adjustment or a closing contingency.

Vehicle age and DOT compliance. NEMT vehicles cycle out faster than other fleet types due to high mileage (50K-80K miles annually per vehicle). Old fleets mean high forward capex. A weighted average fleet age above 5 years will reduce your multiple by 0.5x or more.

No direct MCO contracts. An operator who hasn't pursued any direct contracts with managed care organizations is seen as strategically weak. Even one direct MCO contract demonstrates capability and provides diversification.

How to Maximize Your NEMT Value

Pursue direct MCO contracts aggressively. Every dollar of revenue you shift from broker-sourced to direct MCO is worth 1.5-2x as much at exit. Start this 18-24 months before you want to sell.

Build wheelchair and stretcher capability. Investing in WAVs and stretcher vehicles moves your revenue mix up the acuity curve. Higher margins, higher multiples, more defensible.

Diversify brokers. Don't let any single broker account for more than 40% of revenue. If you're concentrated, actively bid on provider agreements with competing brokers even if the rates are slightly lower.

Document compliance obsessively. Clean billing history, low denial rates, current HIPAA training records, DOT compliance, insurance certificates. Compile all of this into a diligence-ready file before you go to market.

Get the financials clean. Present trip-level revenue data by payer, segregated by service type (ambulatory, WAV, stretcher), with a clean adjusted EBITDA schedule. Buyers want to see unit economics at the trip level, not just consolidated P&L.

Fix driver retention before selling. Wage increases, benefits, and scheduling flexibility that reduce turnover from 50% to under 25% will pay back multiple times at exit.

The Bottom Line

NEMT is the premium asset in the ground transportation space for a reason: contracted revenue, government backstop, demographic tailwinds, and active strategic buyers willing to pay 5-7x EBITDA for operators who've built a clean business. The operators who understand the broker-versus-direct dynamic, who invest in higher-acuity capability, and who prepare for sale 18-24 months in advance are consistently walking away with exits that are meaningfully better than their peers in the rest of the transportation industry. This is one sector where preparation genuinely doubles your outcome.